TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 StudyByPooja Advani, MBBS, MD,Sofia Braga,Adam M. Brufsky, MD, PhD,Karthik V. Giridhar,Erica L. Mayer, MD, MPH,Kelly E. McCann,Ruth M. O’Regan,Cristina Saura,Seth A. Wander,Georg F. Bischof,Beth H. Lowenthal,Judith D. Bebchuk,Lisa D. Eli,Brian G. Barnett,Joyce A. O’Shaughnessy,Tufia C. HaddadApril 11th 2025